同源康医药-B(02410)：ESMO 2025年会公布多项CDK抑制剂临床积极数据
TYK MEDICINESTYK MEDICINES(HK:02410) 智通财经网·2025-10-21 12:16

Core Insights - Company announced early clinical research results for three drugs in the cell cycle protein-dependent kinase inhibitor (CDKi) field, namely TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - Results were presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting, a significant event in the oncology field [1] Company Developments - The company is focusing on the development of CDKi drugs, indicating a strategic emphasis on this therapeutic area [1] - The ESMO 2025 annual meeting will take place from October 17-21, 2025, in Berlin, Germany, highlighting the company's engagement with leading experts in oncology [1]